| Zacks Company Profile for BioCryst Pharmaceuticals, Inc. (BCRX : NSDQ) |
|
|
| |
| • Company Description |
| BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries.
Number of Employees: 580 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $8.88 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 3,145,171 shares |
| Shares Outstanding: 209.25 (millions) |
| Market Capitalization: $1,858.14 (millions) |
| Beta: 1.04 |
| 52 Week High: $11.31 |
| 52 Week Low: $6.02 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
-14.61% |
-17.81% |
| 12 Week |
20.00% |
0.94% |
| Year To Date |
18.08% |
10.59% |
|
|
|
|
| |
|
|
| |
| • General Corporate Information |
Officers
Jon P. Stonehouse - Chief Executive Officer; President and Director
Anthony J. Doyle - Chief Financial Officer
George B. Abercrombie - Director
Stephen J. Aselage - Director
Steven K. Galson - Director
|
|
Peer Information
BioCryst Pharmaceuticals, Inc. (GSAC)
BioCryst Pharmaceuticals, Inc. (CASI)
BioCryst Pharmaceuticals, Inc. (ALCD.)
BioCryst Pharmaceuticals, Inc. (OMNN)
BioCryst Pharmaceuticals, Inc. (CGPI.)
BioCryst Pharmaceuticals, Inc. (CATX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 09058V103
SIC: 2836
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/04/25
|
|
Share - Related Items
Shares Outstanding: 209.25
Most Recent Split Date: (:1)
Beta: 1.04
Market Capitalization: $1,858.14 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $0.05 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $0.12 |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: 6.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: 28.39% |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 08/04/25 |
|
|
|
| |
